Summary.-Protection tests using passively administered antibody have been carried out using 2 mouse lymphomata. The classic model (" Gorer System ") used alloantiserum which was absorbed in vivo to make it tumour specific before use. In order to provide a system suitable for our work, the model was changed by stepwise transitions to tumour specific immunoglobulin made from xenoantiserum absorbed in vitro, since such a procedure is also applicable to human patients. The time lapse used between challenge and treatment in the allo-system was generally ± 2 h but in the xeno-system could be extended to + 18 h. The xenoantisera could not be absorbed in vivo but required 3 to 5 x 103 spleens per 100 ml serum to absorb in vitro to render them tumour specific. The protective antibody was in the IgG (not IgM) fraction of serum. Maximal tumour specific antibody (measured by in vivo protection) appeared after the third injection of rabbits for one lymphoma, but after the fifth for another. The sera were not cross-reactive among 3 lymphomata tested, of which 2 were of the same H-2 genotype.
ANTIBODIES against tumour specific antigens provide the only specifically directed "arrows " for tumour cell targets but their clinical usefulness is far from clarified. When administered passively they are not sufficiently toxic to have much effect on an established tumour; ways of increasing their effectiveness have been studied but the current trend is to stimulate a host's own active cell mediated immunity to tumours. In contrast, in this and the following paper studies of passive humoral immunity are reported.
The nonspecific immunosuppression which is known to accompany tumour growth is not properly understood (Rowland et al., 1971) but it weighs against stimulation of active immunity, as does much of the treatment in cancer which relies on cytotoxic drugs which are themselves immunosuppressive and other treatment, for example x-irradiation, which has similar effects. Yet it is accepted on the basis of experimental results that the immune status of a cancer patient, if properly understood, could be of paramount importance for prognosis.
Immunological protection against strain-specific tumour challenge has been described for many different mouse transplantable tumours. For example Gorer and Amos (1956) used alloantisera absorbed in vivo to protect mice against their own lymphomata and many other workers have used this and similar systems. In this paper transitions are made from alloantiserum to xenoantisera (as Ig) and from in vivo absorption to in vitro absorption, in order to provide a model system suitable for the particular purpose of testing the interactions of drugs and antibodies (Davies, Buckham and Manstone, 1974a; Davies et al., 1974b) .
MATERIALS AND METHODS
Animals and tumours.-EL4 is a lymphoma of C57BL mice which was originally induced with dimethylbenzanthracene (Gorer and Amos, 1956 ) and grows readily as an ascites tumour. EL4 has been extensively studied serologically and has been claimed to have 3 distinguishable specificities not possessed by C57BL/6 mice: These are " X " (Gorer and Amos, 1956) , " E " (Aoki et at., 1970) and " L " (Leclerc et al., 1970) . These cells are TL negative (Boyse, Stockert and Old, 1968) . The lymphoma SB1 arose spontaneously in a Balb/c mouse in our colony; it does not grow as an ascites tumour but enlarges the spleen up to 2 g (wet weight) if injected intraperitoneally or subcutaneously; it does not grow at the site of injection. About 5 cells constitutes a lethal dose in the syngeneic host but 107 cells fail to grow even in other H-2d mice (DBA/2, BIO.D2).
All mice were bred in our own colony. For purposes of immunization rabbits were bought from an accredited dealer.
Immunization.-Antisera were recovered by standard methods but the immunization schedules were varied over a series of experiments and are detailed, where necessary, under the different tests described below. Groups of mice or rabbits were used as recipients for immunization with tumour cells, with normal cells as control, and are described in the text where necessary.
Cytotoxicity.-The cytotoxicity of alloand xenoantisera was assessed on appropriate target cells (lymph node cells or tumour cells) by release of 51Cr label from the cells in the presence of complement. Generally guinea-pig complement has been used and tubes were incubated for 1 h. However, in cases where it has been difficult to obtain a cytotoxic titre against tumour target cells (when none remained after absorption for lymph ncde cells), rabbit complement has been used and incubation times were increased up to 3 h. The test system has been described elsewhere (Albert and Davies, 1973) .
Immunofluorescence.-The interaction of tumour specific rabbit antisera and lymphoma cells was followed in some instances by indirect fluorescence, using a fluorescein conjugated goat anti-rabbit IgG (Flow Laboratories, Irvine KA12 8NB, Scotland, Meloy reagent C406).
Absorption.-In the earlier series of tests described using alloantisera, absorption was carried out in vivo; 1 ml of alloantiserum was injected intraperitoneally into each of a batch of C57BL/6 (for EL4) or Balb/c (for SB1) mice, which were bled from the heart 4 h later. Some serological studies on such absorbed alloantisera have already been described . It was found that even quite small amounts (0-1 ml) of xenoantiserum injected intraperitoneally in mice could not be absorbed owing to some in vivo handling problem. After 4 h, serum could still be recovered from the peritoneal cavity retaining almost its original titre; these sera were frequently also toxic for mice. Some alloand all xenoantisera were therefore absorbed in vitro, mainly using spleen cells but in some cases using liver or membrane preparations (" eluate ") (Davies, 1966 ) from lymphoid tissue. Both liver cell suspensions and eluate were quite difficult to pack down sufficiently by centrifugation in order to avoid substantial losses of absorbed serum volume. In any event, absorption was taken to completion as tested by complement mediated cytotoxicity for normal cells (checked if necessary with rabbit complement and a 3 h incubation time). Thus, for example a serum having a titre of 1/1000 against C57BL/6 lymphocytes was diluted 1: 2 with saline to give a volume of 76 ml and was absorbed thus: with 2f3 g eluate the titre reduced to 1: 200, with a further 1f9 g to 1: 10 and subsequently with 25 C57BL/6 spleens the titre was reduced to zero. Further absorption data were given by Davies and O'Neill (1973) .
As will be seen later in the text, the amount of absorption required depended on the number of injections given to raise a particular serum. In all experiments, antisera were submitted to small scale absorption tests to determine likely requirements before committing whole batches. Generally 3 or 4 absorption stages were needed to remove all cytotoxicity for normal cells. Each stage was monitored in order not to add absorbing material in excess with the prospect of losing tumour specific antibody nonspecifically. When spleens alone were used, 3000-5000 were usually required to absorb fully 100 ml of antiserum. All absorptions included material from mice of the same H-2 genotype as that of the tumour cell used for immunization. Thus, spleens from a variety of mouse strains were used for the bulk absorptions but some H-2d spleens were always included in absorptions of EL4 antisera and some H-2d spleens always included in absorptions of SB1 antisera. This was to remove xeno-antibodies having individual recognition discrimination (Staines et al., 1973) . All sera were centrifuged at 80,000 g for 60 min before use.
Fractionation.-Sera were fractionated with ammonium sulphate (AmSO4) by precipitation at 40% saturation at 4°C. The 40% precipitate was recovered after several hours of equilibration, re-dissolved and reprecipitated at the same level a second time. The " Gorer " sytem using alloantibody, in vivo absorption and administration of whole serum, has been used before to show that EL4 tumour specificity is in the surface membrane material (Davies, 1963 lymphocytes was 1/1200. Serum (62 ml) was absorbed overnight at 4°C at a level of 5 spleens/ml. This absorbed serum was unreactive with Balb/c lymphocytes (using guinea-pig complement and a 3 h incubation time). There was a cytotoxic titre against SB 1 cells with this alloderived serum using guinea-pig complement and a 3 h incubation period (see below). This is not shown because it was similar in magnitude to that already illustrated for EL4 ). This absorbed alloantisertum was fractionated to yield 7-5 ml of immunoglobulin at 20 mg/ml. The results of a protection test using this material are shown in Fig. 3 Table I . Fig. 4 shows that protection can be obtained with xenoantiserum fractionated to Ig and absorbed in vitro to zero cytotoxicity for normal Tumour specific antibody A series of protection tests showed that the potency of different antisera and the ease (or difficulty) with which they could be absorbed differed with the number of immunizing injections. This was tested as follows: rabbits (R96198) were injected i.v. with 108 live EL4 cells 5 times at 10 day intervals and bleedings of 40 ml taken before the second and each subsequent injection. The resulting 5 antisera were heat inactivated and cytotoxicity for normal cells was reduced to zero by absorption as shown in Table II . Using samples of these absorbed sera (checked with rabbit complement and a 3 h incubation time), the titres against EL4 cells varied as shown in Table II . These sera were then examined for their ability to give immunofluorescence of EL4 cells (checking for non-reactivity with normal C57BL/6 cells as control) using a goat Ig antirabbit Ig. The results showed no fluorescence after the first bleeding, a little after bleeding 2, maximal fluorescence after bleeding 3 and persisting submaximally in bleedings 4 and 5. Ammonium sulphate fractionation results are also shown in this Table. The Ig from each bleeding was adjusted to 20 mg/ml for protection testing. A challenge dose of 5 X 104 EL4 cells was given intraperitoneally and 0-2 ml (4 mg) of antibody was given 4 times, the first being 6 h after challenge and then after 24, 48 and 72 h. Thus, the test was made less severe by reducing the time lapse from 18 h (as in the previous test) to 6 h, increasing sensitivity to seek smaller amounts of protective activity. It can be seen from Fig. 5 that the first bleeding had some activity but less than the second, the third was 
Specificity
Whereas we have assessed a number of mouse tumours for their usefulness in test systems of the kind described above, only EL4 and SB1 have been quoted in this paper. An experiment was carried out which showed lack of interaction between EL4 and SB1 systems; a further 21 specificity control using the H-2b lymphoma ERLD which, like EL4, belongs to C57BL/6 mice (Old et al., 1968) was also carried out. A rabbit anti-EL4 serum (R140/145) was used as described above to show that 0 5 ml given 4 times affected the growth of EL4 in C57BL/6 mice adversely and prolonged the lives of mice in this particular test for 9 days (prolongation from Day 15 to Day 24). In the same test, batches of mice were also challenged with ERLD (1 x 105, i.p.); this dose and drug levels were based on ERLD background data of the kind shown in Fig. 1 for EL4 and SB1 and in the following paper describing the drug antibody (" DRAB ") effect (Davies et al., 1974a) . No protection against ERLD was obtained with anti-EL4 antiserum, and small doses of chlorambucil in addition did not show the amplification effect (as seen in Fig. 3 and 4) , presumably because there was nothing to amplify.
DISCUSSION
Protection tests as used by Gorer and Amos (1956) and many other workers in slightly different regimens and with different tumours have been described frequently in the literature. Thus, for example, fractions of EL4 cells were tested for the presence of tumour specific antigen; fractions were injected for active immunization of other mice to obtain allogeneic antisera to test for the presence of protective antibody (Davies, 1963) . The results showed that tumour specificity (" X ") was located in or on the plasma membranes of EL4 tumour cells. Any clinical use of antibody, either alone or in combination with some other treatment, requires assessment in some animal model. There is no special novelty about the model described here, it was merely arranged, to suit our particular requirements, by extending (a) to another tumour (SBI), (b) from alloantisera to xenoantisera, (c) to the use of Ig rather than whole serum, and (d) to absorption in vitro instead of in vivo. These steps worked satisfactorily and have since been used with human material to provide tumour specific immunoglobulin (O'Neill, results to be published).
It will be seen that the number of injections to elicit the best anti-tumour response is both critical and difficult to determine. The number differs from one tumour to another, as seen by direct testing in vivo. It then becomes of great importance to have some in vitro method of assessment and it is interesting to see that both cytotoxicity for EL4 tumour cells (when it was zero for normal cells) and immunofluorescence ran parallel with protective activity when the three were tested on each of a series of antisera. A different number of injections required for the lymphoma SB 1 also gave correlation between cytotoxicity and protection.
Gel filtration was used to show that the tumour specific xenoantibody responsible for protection was not IgM but was in the IgG fraction.
The adjustment of the tests from severe to relative ease as required was achieved by altering the challenge dose, the time lapse between challenge and treatment, or the number and size of treatment injections.
The amplification of the protective effect of antibody by drugs, which was touched on in this paper is expanded upon in a later communication (Davies et al., 1974a) .
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